Abstract
Background
The 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC) and Uganda has challenged epidemic control despite rapid expansion of response capacity.
Objectives
To reassess the threats identified by the ESCMID Emerging Infections Subcommittee at day 100 and identify clinical and public-health priorities.
Sources
This narrative update draws on published literature and WHO, Africa CDC, ECDC, and national public health reports, using 22 August 2026 as the day-100 analytical cut-off, with data through 20 October for a subsequent update.
Content
By 22 August, the DRC had reported 5514 confirmed cases and 2642 deaths in 57 health zones across six provinces, making it the largest recorded outbreak in the DRC and the second-largest Ebola outbreak by confirmed case count. Uganda contained 20 cases, and its outbreak was declared over on 27 August. By 20 October, the DRC had reported 9704 cases and 4687 deaths in 66 health zones across eight provinces; Kenya had reported nine epidemiologically linked cases and Nigeria one. Contact follow-up improved, but many transmission chains remained unidentified. BDBV-specific diagnostics, therapeutic and post-exposure prophylaxis trials, and vaccine studies expanded, yet no vaccine or virus-specific treatment had demonstrated clinical efficacy. Cross-reactive antibody responses after licensed Ebola vaccination do not establish protection against BDBV. ECDC assessed infection likelihood for EU/EEA residents as very low.
Implications
Epidemic control requires complete contact tracing complemented by active case-finding, earlier referral, high-quality supportive care, health-worker protection, community engagement, flexible financing and preservation of essential health services.
Source: Clinical Microbiology and Infection Journal, https://doi.org/10.1016/j.cmi.2026.10.042
____

No comments:
Post a Comment